Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 137

1.

Prospective clinical trial of preoperative sunitinib in patients with renal cell carcinoma.

Hellenthal NJ, Underwood W, Penetrante R, Litwin A, Zhang S, Wilding GE, Teh BT, Kim HL.

J Urol. 2010 Sep;184(3):859-64. doi: 10.1016/j.juro.2010.05.041.

2.

Presurgical sunitinib reduces tumor size and may facilitate partial nephrectomy in patients with renal cell carcinoma.

Lane BR, Derweesh IH, Kim HL, O'Malley R, Klink J, Ercole CE, Palazzi KL, Thomas AA, Rini BI, Campbell SC.

Urol Oncol. 2015 Mar;33(3):112.e15-21. doi: 10.1016/j.urolonc.2014.11.009. Epub 2014 Dec 19.

PMID:
25532471
3.

The effect of sunitinib on primary renal cell carcinoma and facilitation of subsequent surgery.

Rini BI, Garcia J, Elson P, Wood L, Shah S, Stephenson A, Salem M, Gong M, Fergany A, Rabets J, Kaouk J, Krishnamurthi V, Klein E, Dreicer R, Campbell S.

J Urol. 2012 May;187(5):1548-54. doi: 10.1016/j.juro.2011.12.075. Epub 2012 Mar 14.

PMID:
22425095
4.

Computed tomography characteristics of unresectable primary renal cell carcinoma treated with neoadjuvant sunitinib.

Salem ME, Shah SN, Elson P, Garcia JA, Wood LS, Medsinge A, Campbell S, Dreicer R, Rini BI.

Clin Genitourin Cancer. 2014 Apr;12(2):117-23. doi: 10.1016/j.clgc.2013.08.001. Epub 2013 Oct 12.

PMID:
24126239
5.

Performing cytoreductive nephrectomy following targeted sunitinib therapy for metastatic renal cell carcinoma: a surgical perspective.

Shaw GL, Hussain M, Nair R, Bycroft J, Beltran L, Green JS, Powles T, Peters JL.

Urol Int. 2012;89(1):83-8. doi: 10.1159/000338057. Epub 2012 May 16.

6.

Dramatic reduction in tumor burden with neoadjuvant sunitinib prior to bilateral nephron-sparing surgery.

Gorin MA, Ekwenna O, Soloway MS, Ciancio G.

Urology. 2012 Feb;79(2):e11. doi: 10.1016/j.urology.2011.04.018. Epub 2011 Jun 15.

PMID:
21676439
7.

Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma.

Margulis V, Matin SF, Tannir N, Tamboli P, Swanson DA, Jonasch E, Wood CG.

J Urol. 2008 Jul;180(1):94-8. doi: 10.1016/j.juro.2008.03.047. Epub 2008 May 15.

PMID:
18485389
8.

Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma.

Thomas AA, Rini BI, Lane BR, Garcia J, Dreicer R, Klein EA, Novick AC, Campbell SC.

J Urol. 2009 Feb;181(2):518-23; discussion 523. doi: 10.1016/j.juro.2008.10.001. Epub 2008 Dec 18.

PMID:
19100579
9.

Neoadjuvant sunitinib facilitates nephron-sparing surgery and avoids long-term dialysis in a patient with metachronous contralateral renal cell carcinoma.

Ansari J, Doherty A, McCafferty I, Wallace M, Deshmukh N, Porfiri E.

Clin Genitourin Cancer. 2009 Aug;7(2):E39-41. doi: 10.3816/CGC.2009.n.021.

PMID:
19692322
10.

A phase II study of presurgical sunitinib in patients with metastatic clear-cell renal carcinoma and the primary tumor in situ.

Bex A, Blank C, Meinhardt W, van Tinteren H, Horenblas S, Haanen J.

Urology. 2011 Oct;78(4):832-7. doi: 10.1016/j.urology.2011.05.034. Epub 2011 Jul 29.

PMID:
21802123
11.

Sunitinib in patients with metastatic renal cell carcinoma: Birmingham experience.

Ansari J, Fatima A, Fernando K, Collins S, James ND, Porfiri E.

Oncol Rep. 2010 Aug;24(2):507-10.

PMID:
20596640
12.

Safety and efficacy of sunitinib for advanced non-clear cell renal cell carcinoma.

Shi HZ, Tian J, Li CL.

Asia Pac J Clin Oncol. 2015 Dec;11(4):328-33. doi: 10.1111/ajco.12408. Epub 2015 Oct 15.

PMID:
26471774
13.

Response of renal lesions during systemic treatment with sunitinib in patients with metastatic renal cell carcinoma: a single center experience with 14 patients.

Seidel C, Fenner M, Merseburger AS, Reuter C, Ivanyi P, Länger F, Ganser A, Grünwald V.

World J Urol. 2011 Jun;29(3):355-60. doi: 10.1007/s00345-010-0642-3. Epub 2011 Jan 22.

PMID:
21258806
14.
15.

Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy.

Ravaud A, Motzer RJ, Pandha HS, George DJ, Pantuck AJ, Patel A, Chang YH, Escudier B, Donskov F, Magheli A, Carteni G, Laguerre B, Tomczak P, Breza J, Gerletti P, Lechuga M, Lin X, Martini JF, Ramaswamy K, Casey M, Staehler M, Patard JJ; S-TRAC Investigators.

N Engl J Med. 2016 Dec 8;375(23):2246-2254. Epub 2016 Oct 9.

16.

Sunitinib treatment in patients with severe renal function impairment: a report of four cases by the Hellenic Cooperative Oncology Group.

Lainakis G, Bamias A, Psimenou E, Fountzilas G, Dimopoulos MA.

Clin Nephrol. 2009 Jul;72(1):73-8.

PMID:
19640391
17.

Feasibility and efficacy of neoadjuvant sunitinib before nephron-sparing surgery.

Silberstein JL, Millard F, Mehrazin R, Kopp R, Bazzi W, DiBlasio CJ, Patterson AL, Downs TM, Yunus F, Kane CJ, Derweesh IH.

BJU Int. 2010 Nov;106(9):1270-6. doi: 10.1111/j.1464-410X.2010.09357.x.

18.

Early experience with targeted therapy and dendritic cell vaccine in metastatic renal cell carcinoma after nephrectomy.

Dall'Oglio MF, Sousa-Canavez JM, Tanno FY, Tiseo BC, Crippa A, Dos Reis ST, Leite KR, Srougi M.

Int Braz J Urol. 2011 Mar-Apr;37(2):180-5; discussion 185-6.

19.

Sunitinib in patients with metastatic renal cell carcinoma.

Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, Redman BG, Margolin KA, Merchan JR, Wilding G, Ginsberg MS, Bacik J, Kim ST, Baum CM, Michaelson MD.

JAMA. 2006 Jun 7;295(21):2516-24.

PMID:
16757724
20.

Successful treatment of T4 renal cell carcinoma after a neoadjuvant targeted therapy using sunitinib: report of a case.

Ueda K, Noguchi M, Suekane S, Moriya F, Nagayoshi R, Ejima K, Momozono K, Matsuoka K.

Kurume Med J. 2011;58(3):95-8.

Supplemental Content

Support Center